allogeneic

Challenges to address in the CAR-T field 4:58
Challenges to address in the CAR-T field
John Rossi • 26 Aug 2021
Development of personalized tissue-engineered veins 2:54
Development of personalized tissue-engineered veins
Petter Björquist • 14 Oct 2021
Future advancements in tissue engineering 3:16
Future advancements in tissue engineering
Petter Björquist • 14 Oct 2021
How personalized tissue-engineered veins can overcome transplantation problems 1:10
How personalized tissue-engineered veins can overcome transplantation problems
Petter Björquist • 14 Oct 2021
ISCT 2021 highlights: therapeutic deception, global regulation & CAR-T 4:33
ISCT 2021 highlights: therapeutic deception, global regulation & CAR-T
Aaron Levine • 28 May 2021
miCAR: combining microRNA gene silencing with CAR expression 4:17
miCAR: combining microRNA gene silencing with CAR expression
Marco Alessandrini • 20 May 2021
Hypoimmunogenic iPSCs: avoiding immune rejection 5:05
Hypoimmunogenic iPSCs: avoiding immune rejection
Sonja Schrepfer • 27 May 2021
Cardiosphere-derived cells in myocardial regeneration 2:01
Cardiosphere-derived cells in myocardial regeneration
Linda Marban • 19 May 2021
Challenges in developing cord blood- and cord tissue-based therapies 3:48
Challenges in developing cord blood- and cord tissue-based therapies
Joanne Kurtzberg • 22 Jun 2021
Advances in cell-based therapies for MS 4:55
Advances in cell-based therapies for MS
Jakob Dupont • 17 Jun 2021
ATA188: an allogeneic EBV-specific T cell therapy for progressive MS 5:20
ATA188: an allogeneic EBV-specific T cell therapy for progressive MS
Jakob Dupont • 17 Jun 2021
Characterization of ATA188: an off-the-shelf therapy for MS 4:08
Characterization of ATA188: an off-the-shelf therapy for MS
Jakob Dupont • 17 Jun 2021
Optimizing blood supply chain management in cell & gene therapy 4:28
Optimizing blood supply chain management in cell & gene therapy
Delara Motlagh • 1 Jun 2021
Innovations within the CAR T-cell field 1:40
Innovations within the CAR T-cell field
Hong Ma • 19 Feb 2021
Allogenic NKX101 in r/r AML 2:56
Allogenic NKX101 in r/r AML
James Trager • 22 Feb 2021
Avoiding immune rejection of allogeneic iPSCs 3:38
Avoiding immune rejection of allogeneic iPSCs
Sonja Schrepfer • 27 May 2021
The content of VJRegenMed is intended for healthcare professionals